Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Next Steps For Interchangeable Biosimilars: Lifecycle Regulation Policy Development

Executive Summary

US FDA seeks stakeholder views on manufacturing changes, new reference product indications and other questions that build on its draft guidance for approval of interchangeable biosimilars.

You may also be interested in...



Biosimilar Post-Approval Change Guidance Coming From US FDA

Guidance, which is undergoing clearance, will address other products as well and might be released by the end of the year.

Biosimilar Post-Approval Change Guidance Coming From US FDA

Guidance, which is undergoing clearance, will address other products as well and might be released by the end of the year.

Interchangeable Biosimilar Designations Shouldn't Be Forever, Innovators Say

US FDA may need to withdraw previous interchangeability determination due to new indications or manufacturing changes, reference product companies say; generic firms say prior interchangeability designation should apply to new indications absent significant scientific questions.

Related Content

Topics

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel